RZL-012
Sponsors
Raziel Therapeutics Ltd.
Conditions
Dercum DiseaseDercum's Disease LipomasFlank MassLipedemaObesityOverweight and ObesitySubmental FatWeight Loss
Phase 1
An Open Label Study That Will Test Safety and Efficacy of RZL-012 Injection Into the Submental Fat in Chinese vs. Non-Chinese Subjects.
CompletedNCT05466448
Start: 2022-07-29End: 2023-06-15Updated: 2023-12-19
Evaluation the Effects of Various Treatments on RZL-012-Induced Adverse Events
CompletedNCT05476679
Start: 2022-09-25End: 2023-06-12Updated: 2024-01-30
Phase 2
Evaluation of Safety, Efficacy and Thermogenesis-induction of RZL-012 in Overweight and Obese Volunteers
CompletedNCT03171415
Start: 2017-07-25End: 2018-12-28Updated: 2019-08-21
Treatment of Women With Lipedema Involving Substantial Fat Knee of Women and Men With Nodular Dercum's Disease
CompletedNCT03492840
Start: 2018-06-28End: 2019-05-02Updated: 2024-02-08
A Single Blind, Randomized, Placebo-controlled, Phase 2a, 2-cohort Study for the Evaluation of Safety and Efficacy of RZL-012 for Submental Fat Reduction in Healthy Volunteers.
CompletedNCT04086823
Start: 2020-02-25End: 2020-09-16Updated: 2023-11-18
RZL-012 for Dercum's Disease Lipomas
CompletedNCT04229030
Start: 2020-07-30End: 2021-02-20Updated: 2024-02-07
Efficacy and Safety of RZL-012 on Submental Fat Reduction
CompletedNCT04867434
Start: 2021-06-15End: 2022-05-31Updated: 2023-09-28
Evaluation of Safety and Efficacy of RZL-012 in Subjects Seeking Fat Reduction in the Flanks
CompletedNCT05445557
Start: 2022-03-10End: 2022-11-10Updated: 2023-11-18
An Open-label Study That Will Test a Second Treatment Session of RZL-012.
CompletedNCT05763160
Start: 2023-05-29End: 2023-10-20Updated: 2023-11-18